Menu

Report content

Flag "Gaëlle Saint-Hilary: Benefit-risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinoma"

Help us keep the community safe by telling us why this story should be reviewed.

Article

By OrbitShark9913f
Cancel